glp-1 agonists tirzepatide Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis TrimRX | GLP-1 vs GIP:

For example, merely switching from one dose per week (q1wk) to one dose every two weeks (q2wk) maintains roughly 75% of the weight loss

What once represented a specialized class of diabetes treatments has grown into one of the most Continue reading "Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities"

Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity

This review article discusses the potential antidepressant effects of GLP-1RAs, especially in the context of their action on the processes related to neuroprotection, inflammation, stress response, energy metabolism, gut-brain crosstalk and the stability of the gut microbiota

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D